MYIA
TCRT icon

Mount Yale Investment Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Mount Yale Investment Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-107
Closed -$40K – 722
2018
Q3 		$40K Hold
107
– – 0.01% 649
2018
Q2 		$48K Buy
+107
New +$67.8K 0.01% 639

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Mount Yale Investment Advisors's TCRT Position: Q4 2018 in Review

Mount Yale Investment Advisors sold out of Alaunos Therapeutics (TCRT) in Q4 2018, closing a stake of 107 shares — an estimated $40K sold.

Mount Yale Investment Advisors first reported a position in TCRT in Q2 2018 and held it in 2 quarters. The position peaked at $48K in Q2 2018. 137 funds tracked by Wall St. Rank hold TCRT as of Q4 2018.

  • Mount Yale Investment Advisors reported no remaining Alaunos Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Mount Yale Investment Advisors sold 107 Alaunos Therapeutics shares in Q4 2018, an estimated $40K.
  • Mount Yale Investment Advisors first reported a position in Alaunos Therapeutics in Q2 2018 and held it in 2 quarters.
  • Mount Yale Investment Advisors's Alaunos Therapeutics position peaked at $48K in Q2 2018.
  • 137 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2018.

Based on Mount Yale Investment Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.